We have criticised the Scottish Medicines Consortium's (SMC)
decision not to recommend abiraterone for use on the NHS in
Scotland. It follows the National Institute for Health and Clinical
Excellence's (NICE) draft decision to deny the drug for men on the
NHS in England and Wales.